MindBio Therapeutics Corp.
MBIO
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -201.55% | -- | -- | -- | -- |
| Total Revenue | -201.55% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -201.55% | -- | -- | -- | -- |
| SG&A Expenses | -84.16% | -83.74% | -81.98% | -- | -- |
| Depreciation & Amortization | 6,575.00% | 97.50% | -166.67% | -- | -- |
| Other Operating Expenses | -44.20% | -44.20% | 19.03% | -- | -- |
| Total Operating Expenses | -82.39% | -83.05% | -80.75% | -- | -- |
| Operating Income | 74.93% | 82.96% | 80.66% | -- | -- |
| Income Before Tax | 84.61% | 93.67% | 90.48% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 84.61% | 93.67% | 90.48% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1,100.00% | -300.00% | -- | -- | -- |
| Net Income | 84.70% | 93.66% | 90.48% | -- | -- |
| EBIT | 74.93% | 82.96% | 80.66% | -- | -- |
| EBITDA | 145.55% | 204.79% | 166.13% | -- | -- |
| EPS Basic | 80.54% | 94.19% | 92.46% | -- | -- |
| Normalized Basic EPS | 79.78% | 93.88% | 91.98% | -- | -- |
| EPS Diluted | 80.54% | 94.19% | 92.46% | -- | -- |
| Normalized Diluted EPS | 79.78% | 93.88% | 91.98% | -- | -- |
| Average Basic Shares Outstanding | -9.08% | -2.78% | 12.40% | -- | -- |
| Average Diluted Shares Outstanding | -9.08% | -2.78% | 12.40% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
